106 related articles for article (PubMed ID: 33559893)
1. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.
Wang J; Zhang R; Wu X; Li F; Yang H; Liu L; Guo H; Zhang X; Mai H; Li H; Wang Z
Br J Haematol; 2021 May; 193(4):761-768. PubMed ID: 33559893
[TBL] [Abstract][Full Text] [Related]
2. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
[No Abstract] [Full Text] [Related]
3. The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease.
Yin D; Wang J; Wang Z
Ann Hematol; 2024 May; ():. PubMed ID: 38772957
[TBL] [Abstract][Full Text] [Related]
4. PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series.
Chen L; Wang J; Wang Z
Infect Drug Resist; 2024; 17():1545-1550. PubMed ID: 38650754
[TBL] [Abstract][Full Text] [Related]
5. Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis.
Song Y; Zhou F; Du F; Wang Z; Bai L; Yao Y; Liu L; Ma X; Chen S; Wu D; He X
Blood Cancer J; 2024 Apr; 14(1):70. PubMed ID: 38658542
[No Abstract] [Full Text] [Related]
6. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
Chandrakasan S; Jordan MB; Baker A; Behrens EM; Bhatla D; Chien M; Eckstein OS; Henry MM; Hermiston ML; Hinson AP; Leiding JW; Oladapo A; Patel SA; Pednekar P; Ray AK; Dávila Saldaña B; Sarangi SN; Walkovich KJ; Yee JD; Zoref-Lorenz A; Allen CE
Blood Adv; 2024 May; 8(9):2248-2258. PubMed ID: 38429096
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib, IV Immunoglobulin, and High-Dose Glucocorticoids for Critically Ill Adults With Secondary Hemophagocytic Lymphohistiocytosis: A Single-Center Observational Pilot Study.
Scholz L; Posch F; Schulz E; Gornicec M; Wölfler A; Reisinger AC; Reinisch A; Eller P; Eisner F; Kreuzer P; Stradner M; Rosenkranz AR; Krammer F; Schilcher G; Krause R; Hatzl S
Crit Care Explor; 2024 Feb; 6(2):e1046. PubMed ID: 38511127
[TBL] [Abstract][Full Text] [Related]
8. Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study.
Lee BJ
Ther Adv Hematol; 2024; 15():20406207241245517. PubMed ID: 38633898
[TBL] [Abstract][Full Text] [Related]
9. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.
Keenan C; Nichols KE; Albeituni S
Front Immunol; 2021; 12():614704. PubMed ID: 33664745
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome-Hemophagocytic Lymphohistiocytosis.
Horne A; von Bahr Greenwood T; Chiang SCC; Meeths M; Björklund C; Ekelund M; Erensjö P; Berg S; Hagelberg S; Bryceson YT; Andersson U; Henter JI
J Rheumatol; 2021 Oct; 48(10):1596-1602. PubMed ID: 33589555
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies.
Jeha S; Crews KR; Pei D; Peyton M; Panetta JC; Ribeiro RC; Zhao X; Campbell P; Metzger ML; Yang JJ; Cheng C; Pui CH; Bhojwani D
Cancer; 2021 Jun; 127(12):2074-2082. PubMed ID: 33598942
[TBL] [Abstract][Full Text] [Related]
13. Arginine-vasopressin infusion in a child with cranial diabetes insipidus during hyperhydration therapy with chemotherapy: a therapeutic challenge.
Devaraja J; Sloan S; Lee V; Dimitri P
Endocrinol Diabetes Metab Case Rep; 2021 Feb; 2021():. PubMed ID: 33597311
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of two relapsed patients with t(11;19)(q23;p13) acute myeloid leukemia by CLAE chemotherapy sequential with allogeneic hematopoietic stem cell transplantation: Case reports.
Tao S; Song L; Deng Y; Chen Y; Gan Y; Li Y; Ding Y; Zhang Z; Ding B; He Z; Wang C; Yu L
Oncol Lett; 2021 Mar; 21(3):178. PubMed ID: 33574917
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough Candidemia in Pediatric Patients With Cancer From a Brazilian Center.
Barrientos ACM; Nobrega de Almeida Junior J; Litvinov N; Bain V; Cristofani LM; Badue Pereira MF; Sanson Yoshino de Paula C; Lopes Motta A; Rossi F; Bárbaro Del Negro GM; Yamamoto Thomaz D; Sousa Marques HH
Pediatr Infect Dis J; 2021 Mar; 40(3):251-254. PubMed ID: 33565813
[TBL] [Abstract][Full Text] [Related]
16. Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies.
Yildiz H; Bailly S; Van Den Neste E; Yombi JC
Ther Clin Risk Manag; 2021; 17():293-304. PubMed ID: 33888986
[TBL] [Abstract][Full Text] [Related]
17. [Medication compliance for secondary prevention and long-term outcome among patients with acute coronary syndrome after percutaneous coronary intervention in different regions].
Wang X; Li Y; Li J; Qiu MH; Qi ZZ; Li XY; Li YZ; Na K; Han YL
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Feb; 49(2):143-149. PubMed ID: 33611900
[No Abstract] [Full Text] [Related]
18. Wipe-sampling procedure optimisation for the determination of 23 antineoplastic drugs used in the hospital pharmacy.
Guichard N; Boccard J; Rudaz S; Bonnabry P; Fleury Souverain S
Eur J Hosp Pharm; 2021 Mar; 28(2):94-99. PubMed ID: 33608437
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
20. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
George G; Vikman H; Gedeborg R; Lissbrant IF; Garmo H; Styrke J; Van Hemelrijck M; Stattin P
Acta Oncol; 2021 Apr; 60(4):459-465. PubMed ID: 33606571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
